Skip to main content
. 2019 Apr 11;181(1):80–87. doi: 10.1111/bjd.17791

Figure 3.

Figure 3

Illustration of a patient who improved from Investigator's Global Assessment (IGA) 4 (severe) at baseline to IGA 2 (mild) after 16 weeks of dupilumab treatment. Change in IGA score was accompanied by clinically meaningful improvement in BSA, symptoms (sleep, pruritus, POEM) and quality of life. BSA, body surface area; DLQI, Dermatitis Life Quality Index; EASI, Eczema Area and Severity Index; POEM, Patient‐Oriented Eczema Measure.